Please login to the form below

Not currently logged in
Email:
Password:

Astellas withdraws drug application in Japan

Astellas Pharma has withdrawn the marketing application for its venous thromboembolism preventative darexaban in Japan

Astellas Pharma has withdrawn the marketing application for its venous thromboembolism preventative darexaban in Japan, the first market in which it had filed the drug.

The marketing application, which was submitted in late September 2010, had been seeking approval of the oral Factor Xa direct inhibitor for the prevention of venous thromboembolism (VTE) in patients at risk, such as those undergoing orthopaedic surgical procedures in the lower limbs.

Astellas said it was withdrawing the application based on feedback from Japanese regulators that additional clinical trials would be required before the drug could be approved. The marketing application contained two phase II/III studies that compared darexaban to placebo in patients who had elective total knee or hip replacement surgeries in Japan and other Asian countries.

In addition, a North American phase II study for VTE prevention in patients after elective primary knee arthroplasty demonstrated dose-dependent efficacy in VTE prevention, according to the company.

Astellas said it will seek a partner for the development and commercialisation of darexaban for the VTE indication in the US and Europe and for an indication of stroke prevention in atrial fibrillation globally. "Astellas expects to decide future plans, including the indication of VTE in Japan, based on the outcome of the partnership discussion," the company noted.

Darexaban, which was discovered and developed by Astellas, works by directly and selectively inhibiting activated Factor X in the cascade of blood coagulation.

16th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics